Literature DB >> 24553166

Practice bulletin no. 143: medical management of first-trimester abortion.

.   

Abstract

Over the past three decades, medical methods of abortion have been developed throughout the world and are now a standard method of providing abortion care in the United States. Medical abortion, which involves the use of medications rather than a surgical procedure to induce an abortion, is an option for women who wish to terminate a first-trimester pregnancy. Although the method is most commonly used up to 63 days of gestation (calculated from the first day of the last menstrual period), the treatment also is effective after 63 days of gestation. The Centers for Disease Control and Prevention estimates that 64% of abortions are performed before 63 days of gestation (1). Medical abortions currently comprise 16.5% of all abortions in the United States and 25.2% of all abortions at or before 9 weeks of gestation (1). Mifepristone, combined with misoprostol, is the most commonly used medical abortion regimen in the United States and Western Europe; however, in parts of the world, mifepristone remains unavailable. This document presents evidence of the effectiveness, benefits, and risks of first-trimester medical abortion and provides a framework for counseling women who are considering medical abortion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553166     DOI: 10.1097/01.AOG.0000444454.67279.7d

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  26 in total

1.  First-trimester medical abortion practices in Canada: National survey.

Authors:  Edith R Guilbert; Althea S Hayden; Heidi E Jones; Katharine O'Connell White; E Steven Lichtenberg; Maureen Paul; Wendy V Norman
Journal:  Can Fam Physician       Date:  2016-04       Impact factor: 3.275

2.  Abortion Surveillance - United States, 2014.

Authors:  Tara C Jatlaoui; Jill Shah; Michele G Mandel; Jamie W Krashin; Danielle B Suchdev; Denise J Jamieson; Karen Pazol
Journal:  MMWR Surveill Summ       Date:  2018-11-23

3.  Telemedicine and medical abortion: dispelling safety myths, with facts.

Authors:  Roopan Gill; Wendy V Norman
Journal:  Mhealth       Date:  2018-02-01

4.  Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions.

Authors:  Geetika Garg; Navneet Takkar; Alka Sehgal
Journal:  J Obstet Gynaecol India       Date:  2014-10-31

5.  Induction of Labour. Guideline of the DGGG, OEGGG and SGGG (S2k, AWMF Registry No. 015-088, December 2020).

Authors:  Sven Kehl; Irene Hösli; Ulrich Pecks; Philipp Reif; Ralf L Schild; Markus Schmidt; Dagmar Schmitz; Christiane Schwarz; Daniel Surbek; Michael Abou-Dakn
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-08-09       Impact factor: 2.754

Review 6.  Medication Abortion Through Telemedicine: Implications of a Ruling by the Iowa Supreme Court.

Authors:  Y Tony Yang; Katy B Kozhimannil
Journal:  Obstet Gynecol       Date:  2016-02       Impact factor: 7.661

7.  Contraception after medication abortion in the United States: results from a cluster randomized trial.

Authors:  Corinne H Rocca; Suzan Goodman; Daniel Grossman; Kara Cadwallader; Kirsten M J Thompson; Elizabeth Talmont; J Joseph Speidel; Cynthia C Harper
Journal:  Am J Obstet Gynecol       Date:  2017-10-03       Impact factor: 8.661

Review 8.  Medication to Manage Abortion and Miscarriage.

Authors:  Jessica Beaman; Christine Prifti; Eleanor Bimla Schwarz; Mindy Sobota
Journal:  J Gen Intern Med       Date:  2020-05-14       Impact factor: 5.128

9.  Abortion Surveillance - United States, 2015.

Authors:  Tara C Jatlaoui; Maegan E Boutot; Michele G Mandel; Maura K Whiteman; Angeline Ti; Emily Petersen; Karen Pazol
Journal:  MMWR Surveill Summ       Date:  2018-11-23

Review 10.  Prioritisation of outpatient appointments and elective surgery in gynaecology.

Authors:  Bibi Zeyah Fatemah Sairally; T Justin Clark
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2021-03-18       Impact factor: 5.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.